Wednesday, May 18 2022


Virtual Corporate Presentation – October 14, 2021 – 10 a.m. ET

Content of the article

CALGARY, Alberta, October 14, 2021 (GLOBE NEWSWIRE) – XORTX Therapeutics Inc. (” XORTX “or the” Society ”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapy company focused on developing innovative therapies to treat progressive renal failure, announces its participation in the LD Micro Main Event, to be held October 12-14, 2021 .

Dr Allen Davidoff said: “LD Micro is a conference of leading MicroCap investors, we are delighted to be invited to present to their investor groups which include institutions, family offices and science analysts from life.

Advertising

Content of the article

Chris Lahiji, Founder of LD Micro, added, “We are honored to be back in person with some of the best companies and investors in the small cap world. After nearly two years, for my part, I can’t wait to reconnect as an executive, events coordinator and investor all at the same time.

Participant registration link:

XORTX Therapeutics – LD Micro Main Event: October 14, 2021 at 10 a.m.ET

A replay of the presentation will be posted in the Investor Relations section of the Company’s website at https://www.xortx.com/investors/.

About LD Micro

LD Micro aims to be the most critical resource in the world of micro-caps. Whether it’s indexes, comprehensive data, or hosting the most important events every year, LD’s sole mission is to be an invaluable tool for anyone looking to find the next generation of great companies.

Advertising

Content of the article

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for coronavirus / COVID-19 infection and XRx-225 is a program preclinical stage for type 2 diabetic nephropathy (T2DN). XORTX is working to advance its products into clinical development that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit uric acid production. At XORTX Therapeutics, we are committed to developing drugs to improve the quality of life and future health of patients. Additional information about XORTX Therapeutics is available at www.xortx.com.

For more information, please contact:

The CSE and the Nasdaq have neither approved nor disapproved the contents of this press release. No stock exchange, securities commission or other regulatory authority has approved or disapproved of the information contained in this document.

Main logo

Advertising

comments

Postmedia is committed to maintaining a lively but civil discussion forum and encourages all readers to share their views on our articles. Comments may take up to an hour of moderation before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread that you follow, or if a user that you follow comments. Check out our community guidelines for more information and details on how to adjust your email settings.


Previous

Launch of a new division in a software supplier for the entertainment industry

Next

Marjaree Mason Center Honors 10 Leading Business Women at Luncheon

Check Also